CORONA Remedies: Trading Window Closed from April 1 for Q4/FY26 Results
CORONA Remedies Limited will close its trading window from April 1, 2026, until 48 hours after the declaration of its audited financial results for Q4 and FY26, ending March 31, 2026. The board meeting date for result declaration will be intimated later.
This is a standard regulatory procedure and does not provide new information about the company's performance or future prospects, hence having a low impact on investors.
The announcement is a routine regulatory disclosure regarding the closure of the trading window and does not contain any material financial or operational information that would impact the sentiment.
CORONA Remedies Limited has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015.
The trading window will be shut effective from April 01, 2026. It will remain closed until 48 hours after the declaration of the audited financial results for the fourth quarter and the full financial year ending on March 31, 2026.
The company stated that the date of the Board Meeting, where the audited financial results will be considered, will be intimated separately in due course.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under trading window disclosure. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.